Annual report [Section 13 and 15(d), not S-K Item 405]

REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Details)

v3.26.1
REVISION OF PRIOR PERIOD FINANCIAL STATEMENTS (Details) - USD ($)
Dec. 31, 2025
Sep. 30, 2025
Jun. 30, 2025
Dec. 31, 2024
Dec. 31, 2023
Current assets:          
Cash $ 139,360 $ 287,688   $ 88,033 $ 65,222
Accounts receivable, net 253,459     0  
Grant receivable 52,026     0  
Inventory 143,425     0  
Prepaid expenses 226,198     29,963  
Total current assets 814,468     117,996  
Property and equipment, net 4,062     18,977  
Right to use assets 159,128     199,184  
Other assets:          
Intangible assets, net 564,460     7,848  
Goodwill 563,158     0  
Deposits, long term 41,936     41,936  
Total other assets 1,169,554     49,784  
Total assets 2,147,212     385,941  
Current liabilities:          
Accounts payable and accrued expenses 6,362,728     5,574,831  
Deferred revenue-grant 0     56,590  
Lease liability, short term 43,382     40,057  
Notes payable, net of debt discounts 1,222,730     1,343,278  
Notes payable, related parties, net of debt discount 677,359     1,192,859  
Total current liabilities 8,306,199     8,207,615  
Long term liabilities:          
Upfront purchase price liability 42,503     0  
Royalty liability 359,378     0  
Lease liability, long term 115,745     159,127  
Total liabilities 13,674,200     12,741,173  
Deficit:          
Common stock value 24,489     13,299  
Common stock subscribed 100,000     100,000  
Additional paid in capital 75,279,624     70,953,807  
Accumulated deficit (86,649,288)     (83,209,142)  
Total deficit attributable to BioCorRx, Inc. (11,223,559)     (12,120,420)  
Non-controlling interest (303,429)     (234,812) (128,834)
Total deficit (11,526,988)     (12,355,232) $ (9,952,524)
Total liabilities and deficit 2,147,212     385,941  
As Revised [Member]          
Current assets:          
Cash   287,688   88,033  
Accounts receivable, net   159,442      
Grant receivable   761,515      
Inventory   155,367      
Prepaid expenses   63,164      
Total current assets   1,427,176      
Property and equipment, net   7,685      
Right to use assets   169,443      
Other assets:          
Intangible assets, net   3,011,833      
Goodwill   2,840,400      
Deposits, long term   41,936      
Total other assets   5,894,169      
Total assets   7,498,473      
Current liabilities:          
Accounts payable and accrued expenses   12,403,767      
Deferred revenue-grant   56,590      
Lease liability, short term   42,525      
Notes payable, net of debt discounts   1,547,853      
Notes payable, related parties, net of debt discount   991,059      
Total current liabilities   15,041,794      
Long term liabilities:          
Economic Injury Disaster loan, long term   69,803      
Upfront purchase price liability   85,440      
Royalty liability   317,577      
Royalty obligation, net of discount   4,659,064      
Lease liability, long term   126,918      
Total liabilities   20,300,596      
Deficit:          
Preferred stock, no par value, 600,000 authorized   0      
Common stock value   20,188      
Common stock subscribed   100,000      
Common stock subscription receivable   (35,000)      
Common stock subscription receivable   35,000      
Additional paid in capital   73,575,399      
Accumulated deficit   (86,131,058)      
Total deficit attributable to BioCorRx, Inc.   (12,448,855)      
Non-controlling interest   (353,268)      
Total deficit   (12,802,123) $ (13,013,229)    
Total liabilities and deficit   7,498,473      
Revision [Member]          
Current assets:          
Cash   0   0  
Accounts receivable, net   35,000      
Grant receivable   0      
Inventory   0      
Prepaid expenses   0      
Total current assets   35,000      
Property and equipment, net   0      
Right to use assets   0      
Other assets:          
Intangible assets, net   0      
Goodwill   0      
Deposits, long term   0      
Total other assets   0      
Total assets   35,000      
Current liabilities:          
Accounts payable and accrued expenses   2,828      
Deferred revenue-grant   0      
Lease liability, short term   839      
Notes payable, net of debt discounts   0      
Notes payable, related parties, net of debt discount   0      
Total current liabilities   3,667      
Long term liabilities:          
Economic Injury Disaster loan, long term   0      
Upfront purchase price liability   0      
Royalty liability   0      
Royalty obligation, net of discount   0      
Lease liability, long term   839      
Total liabilities   2,828      
Deficit:          
Preferred stock, no par value, 600,000 authorized   0      
Common stock value   0      
Common stock subscribed   0      
Common stock subscription receivable   (35,000)      
Common stock subscription receivable   35,000      
Additional paid in capital   (1)      
Accumulated deficit   1,070,785      
Total deficit attributable to BioCorRx, Inc.   1,035,784      
Non-controlling interest   (1,073,612)      
Total deficit   (37,828) $ 0    
Total liabilities and deficit   35,000      
As Reported [Member]          
Current assets:          
Cash   287,688      
Accounts receivable, net   194,442      
Grant receivable   761,515      
Inventory   155,367      
Prepaid expenses   63,164      
Total current assets   1,462,176      
Property and equipment, net   7,685      
Right to use assets   169,443      
Other assets:          
Intangible assets, net   3,011,833      
Goodwill   2,840,400      
Deposits, long term   41,936      
Total other assets   5,894,169      
Total assets   7,533,473      
Current liabilities:          
Accounts payable and accrued expenses   12,400,939      
Deferred revenue-grant   56,590      
Lease liability, short term   41,686      
Notes payable, net of debt discounts   1,547,853      
Notes payable, related parties, net of debt discount   991,059      
Total current liabilities   15,038,127      
Long term liabilities:          
Economic Injury Disaster loan, long term   69,803      
Upfront purchase price liability   85,440      
Royalty liability   317,577      
Royalty obligation, net of discount   4,659,064      
Lease liability, long term   127,757      
Total liabilities   20,297,768      
Deficit:          
Preferred stock, no par value, 600,000 authorized   16,000      
Common stock value   20,188      
Common stock subscribed   100,000      
Common stock subscription receivable   0      
Common stock subscription receivable   0      
Additional paid in capital   73,575,400      
Accumulated deficit   (87,201,843)      
Total deficit attributable to BioCorRx, Inc.   (13,484,639)      
Non-controlling interest   720,344      
Total deficit   (12,764,295)      
Total liabilities and deficit   7,533,473      
Series B Convertible Preferred Stock [Member]          
Deficit:          
Preferred stock, no par value, 600,000 authorized 5,616 5,616   5,616  
Series B Convertible Preferred Stock [Member] | As Revised [Member]          
Deficit:          
Preferred stock, no par value, 600,000 authorized   5,616      
Series B Convertible Preferred Stock [Member] | Revision [Member]          
Deficit:          
Preferred stock, no par value, 600,000 authorized   0      
Series A Convertible Preferred Stock [Member]          
Deficit:          
Preferred stock, no par value, 600,000 authorized $ 16,000     $ 16,000  
Series A Convertible Preferred Stock [Member] | As Revised [Member]          
Deficit:          
Preferred stock, no par value, 600,000 authorized   16,000      
Series A Convertible Preferred Stock [Member] | Revision [Member]          
Deficit:          
Preferred stock, no par value, 600,000 authorized   $ 0